• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

DNDi is joining a drug discovery project on mycetoma supported by the Novo Nordisk Foundation

10 Jul 2026

Led by Erasmus MC in the Netherlands, the project ‘Unravelling host-pathogen pathways in mycetoma: the route towards novel diagnostic tools and therapies for controlling mycetoma globally (UNRAVELMy)’ and is the first of its kind large-scale fundamental research study for mycetoma, a fungal infection that is one of the world’s most neglected diseases.   

This international collaboration will create a large biobank of mycetoma samples, bringing together research institutions in Sudan, Senegal, Belgium, Denmark, Ireland, the Netherlands, Switzerland, and the United Kingdom. By studying the fungus and the human immune response, the project aims to identify biological markers that could help improve diagnosis, monitor whether treatments are working, and identify new targets for drug development.   

Despite recent progress, including the DNDi-led development of fosravuconazole in Sudan, treatments for eumycetoma still require months of treatment and often surgery, with significant room for improvement. 

Mycetoma is neglected not only in terms of available treatments, but also in the understanding of the disease itself. Investing in fundamental research is therefore essential to build the scientific foundations needed to develop the next generation of diagnostics and treatments, and ultimately improve outcomes for patients.

More information on the project: Mycetoma Translational platform | DNDi
Novo Nordisk announcement: No easy answers: European research consortia take on major challenges – Novo Nordisk Fonden

Funding Mycetoma Africa Europe

Read, watch, share

Loading...
Publications
6 Nov 2026

Extreme heat and climate-sensitive infectious diseases

News
2 Nov 2026

Project to develop dengue treatment pre-selected by the Global Coalition for Local and Regional Production, Innovation, and Equitable Access

close up of a scientist holding tools they are wearing blue gloves
Press releases
29 Oct 2026

DNDi welcomes GHIT Fund’s support for innovative approaches to improve success in Chagas disease drug discovery with Nagasaki University, the University of Dundee, and Eisai 

Press releases
27 Oct 2026

Kenya becomes first African country to join the Dengue Alliance

News
9 Oct 2026

DNDi 2026 Projects of the Year recognize teams and partners for their work to advance an open-science antiviral for future coronavirus pandemics and a single-dose treatment for sleeping sickness

Press releases
6 Oct 2026

Ghana’s KNUST and DNDi partner to accelerate drug discovery for neglected diseases in Africa

Statements
25 Sep 2026

DNDi intervention at the UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response at the 81st UN General Assembly

News
15 Sep 2026

New DNDi report: Implementing Article 9.5 of the WHO Pandemic Agreement – building on current policy and practice for publicly funded R&D

VIEW ALL

Help neglected patients

To date, we have delivered seventeen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Youtube Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license